How the GLP-1 super-cycle is opening a new aesthetics super-category, and why Conexeu Sciences (Nasdaq: CNXU) is engineered for the gap a 30-year-old toolkit cannot fill.
We just sent the investor briefing to your email. If you don't see it within a few minutes, check your spam folder.
Download the PDF nowThe complete report unpacks why we believe a stagnant aesthetics industry meeting a brand-new wave of demand has historically rewarded the small company with a different idea, and how Conexeu Sciences (Nasdaq: CNXU) is potentially positioned to define the new category.
Why $63B aesthetics buyouts (AbbVie/Allergan, EQT/Galderma) suggest the next category-creating franchise could be the most valuable trade of the decade.
"Ozempic face," peer-reviewed evidence of five-years-older appearance after rapid weight loss, and a new patient cohort that may outpace the legacy aesthetic toolkit.
Three independent third-party sources, in our view, point to the same shape: a potentially significant structural increase in spend driven by the convergence of GLP-1 adoption and aesthetic demand.
Roughly 90% of dermal-filler procedures globally still rely on hyaluronic acid. The FDA describes the mechanism in plain English. Side-by-side comparison inside.
An injectable bioregenerative extracellular matrix (ECM) scaffold designed to restore soft tissue lost through aging, injury, and GLP-1-associated weight loss.
Medical aesthetics (~$11B), wound care (~$2.6B), dental soft tissue (~$4.2B), veterinary (~$1.4B), and 3D bioprinting (~$1.6B), from one patent-protected formulation.
A CEO who ran Galderma North America. A CMO with prior senior roles at the makers of two of the three U.S. biostimulators. An MD-PhD surgeon-scientist as Co-Founder & CSO.
The macro super-cycle, the documented unmet need, the 510(k) regulatory route, the global patent estate, and the strategic-buyer landscape that has, twice this decade, written ten- and eleven-figure checks.
"Post-GLP-1 body management is going to emerge as its own category … expanding into regenerative and tissue-health applications as millions of GLP-1 patients seek solutions for laxity rather than volume loss."
Conexeu Sciences (Nasdaq: CNXU) just began trading. Get the full 10-page investor briefing, with stats, sourcing, side-by-side comparisons, and the eight reasons we believe CNXU belongs on the watchlist.